DiaSorin offers the LIAISON® BRAHMS PCT® II GEN on the LIAISON® systems.
LIAISON® BRAHMS PCT® II GEN assay uses chemiluminescence immunoassay (CLIA) technology for the in vitro quantitative determination of Procalcitonin in human serum and plasma specimens. The assay is intended for use, in conjunction with other laboratory findings and clinical assessments, to aid in the risk analysis of critically ill patients for progression of relevant bacterial infections.
Sepsis can be difficult to distinguish from other non-infectious conditions in critically ill patients with clinical sign of acute inflammation. However, therapies and outcomes may differ significantly between patients with and without sepsis.
Among the potentially available laboratory parameters, Procalcitonin (PCT) has the highest diagnostic accuracy. PCT levels rise rapidly as a response to severe systemic infections and sepsis. This allowing clinicians to differentiate sepsis from other non-infectious conditions. Levels of PCT tested can properly address antibiotics therapy. Having an accurate PCT level will allow correct dosing of antibiotic therapy.
In conjunction with other laboratory findings PCT levels can help in identifying systemic bacterial infections (sepsis) from severe sepsis and/or septic shock. For each category of illnesses an appropriate clinical cut-off is to be used.